Month: September 2026

On 12 May 2026, Gabriel Holding A/S initiated a share buy-back programme. The buy-back runs from 12 May 2026 up to and including 16 March 2027. During this period, Gabriel Holding A/S may repurchase up to 94,500 shares corresponding to 5% of the share capital.

Gabriel Holding A/S held 55,109 treasury shares at the start of the share buyback programme.

The buy-back is executed in accordance with Article 5 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulation. The buy-back is carried out on Nasdaq Copenhagen at market price and in accordance with the authorization granted by the general meeting, Nasdaq Copenhagen’s rules for issuers, as well as Gabriel Holding A/S’ internal rules on insider matters and handling of inside information.

The following transactions have been carried out under the programme during the period below:

	Number of shares	Average purchase price	Transaction value in DKK
Treasury shares before start of programme	55.109
Accumulated under the programme in accordance with the latest announcement	7,244	268.82	1,947,362
Monday, 21 September 2026	80	224.88	17,990
Tuesday, 22 September 2026	80	216.50	17,320
Wednesday, 23 September 2026	80	214.00	17,120
Thursday, 24 September 2026	80	211.00	16,880
Accumulated under the programme in accordance with the above transactions	7,564	266.61	2,016,673

With the above transactions, the company’s holding of treasury shares amounts to 62,673 shares, corresponding to 3.32% of the total number of issued shares of 1,890,000.

Inquiries and further information:
CEO Anders Hedegaard Petersen, phone +45 9630 3117

Appendix

Detailed data on share buy-back transactions is enclosed in accordance with Commission Delegated Regulation (EU) 2016/1052 supplementing Regulation (EU) No. 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the conditions applicable to buy-back programmes and stabilisation measures, Article 2. All transactions have been carried out by Danske Bank A/S on behalf of Gabriel Holding A/S.

Volume	Price	Venue	Time – GMT	Time – CET
25	224	XCSE	20260921 09:19:51.612903 +0100s	20260921 10:19:51.612903
20	226	XCSE	20260921 13:06:35.628201 +0100s	20260921 14:06:35.628201
15	226	XCSE	20260921 13:56:36.575021 +0100s	20260921 14:56:36.575021
20	224	XCSE	20260921 14:15:40.859841 +0100s	20260921 15:15:40.859841
40	216	XCSE	20260922 10:42:53.392098 +0100s	20260922 11:42:53.392098
20	214	XCSE	20260922 11:40:50.333250 +0100s	20260922 12:40:50.333250
20	220	XCSE	20260922 14:44:56.614822 +0100s	20260922 15:44:56.614822
80	214	XCSE	20260923 14:53:31.916713 +0100s	20260923 15:53:31.916713
28	212	XCSE	20260924 11:04:49.964864 +0100s	20260924 12:04:49.964864
12	212	XCSE	20260924 13:00:26.626985 +0100s	20260924 14:00:26.626985
6	210	XCSE	20260924 14:48:28.192333 +0100s	20260924 15:48:28.192333
34	210	XCSE	20260924 15:17:38.180901 +0100s	20260924 16:17:38.180901

This is a translation of the original Danish text. In the event of discrepancies between the Danish and English texts, the Danish version shall prevail.

Attachment

• Gabriel Holding AS – Announcement no 30 – share buy back week 39

To the Nasdaq Copenhagen

Prepayments (CK93)

Pursuant to s 24 of the Danish Capital Markets Act, Totalkredit A/S hereby publishes prepayment data (CK93) as at 25 September 2026 in the attached file.

Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/.

For further information about data format and contents, please refer to the Nasdaq website.

Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21.

Yours sincerely
Totalkredit A/S

Attachments

• Prepayments – Totalkredit A_S_28-09-2026
• eordindftk_28092026

To the Nasdaq Copenhagen

Prepayments (CK93)

Pursuant to s 24 of the Danish Capital Markets Act, Nykredit Realkredit A/S hereby publishes prepayment data (CK93) as at 25 September 2026 in the attached file.

Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/.

For further information about data format and contents, please refer to the Nasdaq website.

Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21.

Yours sincerely
Nykredit Realkredit A/S

Attachments

• Prepayments – Nykredit Realkredit A_S_28-09-2026
• eordindf_28092026

Amsterdam, 28 September 2026

EXOR N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM

Exor N.V. (AMS: EXO) (“Exor” or the “Company”) announces that, under the first tranche of the share buyback program of up to €125 million announced on 23 September 2026 (the “First Tranche”), the Company has completed the following transactions on Euronext Amsterdam, CBOE DXE, Turquoise Europe and Aquis Exchange Europe:

EURONEXT AMSTERDAM

Trading Date	Number of ordinary shares purchased	Average price per share excluding fees (€)	Total consideration excluding fees (€)
23 September 2026	39,516	72.65	2,870,676.93
24 September 2026	41,464	71.76	2,975,371.14
25 September 2026	41,363	70.85	2,930,700.37
TOTAL	122,343		8,776,748.44

CBOE DXE

Trading Date	Number of ordinary shares purchased	Average price per share excluding fees (€)	Total consideration excluding fees (€)
23 September 2026	27,151	72.64	1,972,159.57
24 September 2026	28,573	71.74	2,049,689.21
25 September 2026	27,636	70.87	1,958,453.47
TOTAL	83,360		5,980,302.25

TURQUOISE EUROPE

Trading Date	Number of ordinary shares purchased	Average price per share excluding fees (€)	Total consideration excluding fees (€)
23 September 2026	4,010	72.63	291,233.08
24 September 2026	4,082	71.85	293,280.90
25 September 2026	4,037	70.89	286,173.28
TOTAL	12,129		870,687.25

AQUIS EXCHANGE EUROPE

Trading Date	Number of ordinary shares purchased	Average price per share excluding fees (€)	Total consideration excluding fees (€)
23 September 2026	5,710	72.67	414,941.82
24 September 2026	5,037	71.75	361,426.30
25 September 2026	4,604	70.85	326,188.93
TOTAL	15,351		1,102,557.05

After these purchases, the total invested amount under the first tranche is approximately €17 million for a total amount of 233,183 ordinary shares purchased.

As of 28 September 2026, the Company held in total 5,271,559 ordinary shares in treasury (2.54% of total ordinary issued share capital)¹.

A comprehensive overview of the transactions carried out under the share buyback program, as well as the details of the above transactions, are available on Exor’s corporate website under the Share Buyback section.

¹ This corresponds to 0.78% of the total issued share capital including both ordinary shares and special voting shares.

Attachment

• Exor Press Release – W40-26 Buyback

September 28, 2026
News release

Unlocking the Growth – Invitation to BioPorto’s investor meeting on October 7 

As BioPorto continues to advance its commercial strategy and capitalize on emerging clinical opportunities, we invite you to join us for an afternoon focused on the key drivers that may shape the Company’s future.

At the event, management will provide an update on BioPorto’s commercial progress, regulatory initiatives, strategic priorities, and path toward sustainable growth and cash flow positivity. Participants will also hear independent perspectives from leading clinical experts and capital market specialists on the opportunities created by biomarker-guided diagnostics and the updated KDIGO guidelines.

Key topics include:
✅ Commercial momentum and strategic priorities
✅ Adult Clinical Validation Study update
✅ What the new KDIGO guidelines could mean for biomarker adoption
✅ External perspectives on BioPorto’s investment case and future value drivers
✅ Live Q&A with management and guest speakers

Wednesday, October 7, 2026
3:00 PM – 5:30 PM CET (Registration from 2:30 PM)
 BioPorto A/S, Tuborg Havnevej 15, 2900 Hellerup, Denmark

Register today to secure your participation and gain first-hand insights into BioPorto’s strategy, clinical progress, and future growth opportunities.
Register in the link in the invitation attached or via this link: https://lnkd.in/ej4e8P65

We look forward to welcoming you to BioPorto.

For further information, please contact:

BioPorto A/S
Klaus Juhl Wulff, BioPorto A/S, investor@bioporto.com, C: +45 25 63 39 90

About BioPorto
BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment

• bioporto-ir-event-invitation-oct-7th-2026